NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Clinical trials for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New gene therapy offers hope for Tough-to-Treat bladder cancer
Disease control Recruiting nowThis study is testing a new gene therapy called EG-70 for people with non-muscle invasive bladder cancer who haven't responded well to standard BCG treatment or are ineligible for it. The therapy is delivered directly into the bladder to stimulate the immune system to fight cance…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE1, PHASE2 • Sponsor: enGene, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New gene therapy trial aims to save bladders from cancer
Disease control Recruiting nowThis Phase 3 trial is testing a gene therapy called nadofaragene firadenovec for people with a high-risk form of bladder cancer that has not responded to the standard BCG treatment. The study will see if the therapy, given alone or combined with chemotherapy or immunotherapy, can…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC